Search the Newsreel

SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary

Spruce Biosciences, Inc. (SPRB) reported a significantly widened net loss of $(16.2M) in 2Q 2026, compared to $(2.1M) in 2Q 2025, with diluted loss per share increasing to $(6.68). The company did not report revenue but highlighted regulatory progress with TA-ERT receiving FDA Breakthrough …

Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M

Spruce Biosciences (SPRB) reported an increased net loss of $28.5 million for the first half of 2026, up from $16.1 million in 2025, primarily due to higher research and development expenses for its lead asset, tralesinidase alfa (TA-ERT). Despite increased spending, the company significantly …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings

Emergent BioSolutions' Executive Vice President and Chief Growth Officer, Stephanie Duatschek, has reported her initial equity holdings, which include 197,416 shares of common stock and various employee stock options. Her holdings comprise 55,639 direct common shares and 141,777 unvested Restricted Stock Units (RSUs), with …

Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance

Spruce Biosciences GAAP EPS of -$6.68

* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symbol/SPRB]): Q2 GAAP EPS of -$6.68. * Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. * Spruce believes that its cash and cash equivalents …

Spruce Biosciences: Q4 Biologics Filing Anticipated; Child Study Expected

Spruce Biosciences receives $5.5M from patient advocacy groups

Spruce Biosciences (NASDAQ:SPRB) has secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society. This funding will partially support an expanded access program for its investigational therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT), aimed at patients with Sanfilippo …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages

Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price

Analysts Offer Predictions for AURA Q1 Earnings

Medios steigert Umsatz im ersten Halbjahr 2026 auf über 1 Milliarde Euro, senkt aber die Gewinnprognose

Helios Towers Sets Dollar Exchange Rate for 2026 Interim Dividend

Equities Analysts Set Expectations for PCRX Q3 Earnings

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

HC Wainwright has revised its Q3 2026 earnings estimate for Solid Biosciences (NASDAQ:SLDB), predicting a narrowed loss of $0.38 per share and maintaining a "Buy" rating with a $25 price target. The firm anticipates Solid Biosciences will become profitable by 2029, projecting earnings of …

Aroa Biosurgery (ASX:ARX) Profit Milestone Shifts Focus to US Growth Strategy

Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Helios Technologies, Inc $HLIO Stake Cut by Wasatch Advisors LP

Wasatch Advisors LP significantly reduced its stake in Helios Technologies (HLIO) by 17.4% in the second quarter, selling 138,923 shares but still retaining a substantial holding valued at approximately $58.9 million. This comes as Helios Technologies exceeded its second-quarter earnings and revenue expectations, and …

(PCRX) and the Role of Price-Sensitive Allocations

This article analyzes Pacira Biosciences Inc

Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend

Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH

(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform …

E. Ohman J or Asset Management AB Makes New Investment in Twist Bioscience Corporation $TWST

E. Ohman J or Asset Management AB has initiated a new position in Twist Bioscience Corporation, acquiring 8,287 shares valued at approximately $853,000. This investment comes as other major institutional investors, such as ARK Investment Management and Millennium Management, have also increased their holdings …

BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39

BofA Securities has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) but has revised its price target downward to $39. This adjustment reflects an updated outlook from the firm regarding the company's valuation.

Harvard Bioscience Releases Q2 2026 Financial Results

Harvard Bioscience (HBIO) reported its Q2 2026 financial results, showing a narrower-than-expected adjusted loss of $0.14 per share, beating analyst estimates. Revenue increased by 10.7% to $22.7 million. The company attributes this improvement to steady demand for its laboratory equipment and instruments, reflecting stabilization …

Medios setzt Wachstumskurs im 1. Halbjahr 2026 fort und richtet Fokus auf Profitabilität und Cash Conversion

EQS-News: Medios setzt Wachstumskurs im 1. Halbjahr 2026 fort und richtet Fokus auf Profitabilität und Cash Conversion - boerse.de

Village Farms International And 2 Other Penny Stocks Worth Watching

This article highlights three penny stocks—Village Farms International (VFF), NovaBridge Biosciences (NBP), and Quanterix (QTRX)—as potential investment opportunities. It details each company's financial health, operational focus, recent performance, and growth prospects, emphasizing their unique positions within their respective markets. The market as a whole …

Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-08-12

Harvard Bioscience, Inc. (HBIO) published its slide deck in conjunction with its Q2 2026 earnings call. The company reported an EPS of -$0.14, beating estimates by $0.07, and revenue of $22.73M, which was an 11.13% year-over-year increase and beat by $1.28M. This article provides …

Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake

Qiming funds have reported a significant ownership stake in Alamar Biosciences, Inc. (ALMR) through a Schedule 13G filing. Qiming Corporate GP VI, Ltd and related entities collectively hold 10.2% beneficial ownership, translating to 7,066,573 shares based on 69,311,186 shares outstanding as of April 30, …

Helios Technologies (HLIO) Stock Faces Margin Reset Versus Rich P E

Jade Biosciences Is Maintained at Buy by BTIG

BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.